Compounded Retatrutide: Is It Legal, Real, or Safe?
By The RX Index Editorial Team · Last verified October 14, 2026
No. As of October 14, 2026, no U.S. pharmacy can legally make compounded retatrutide for patients. The FDA says retatrutide "cannot be used in compounding under federal law". It isn't FDA-approved and doesn't meet the ingredient rules. A prescription, lab report, or "licensed pharmacy" label doesn't change that.
The two verified paths to real retatrutide today are a Lilly clinical trial or a narrow, doctor-requested program called expanded access. Lilly plans to ask the FDA for approval in the first quarter of 2027. That is a filing plan, not an approval date.
If an offer is open in another tab, the table below checks 10 common seller claims. After that, we'll show you what to compare next, with prices and payment terms we checked this month.
One honest limit up front: no web page can test what's in a vial, including this one. What we can do is show you what the rules, the regulators, and Lilly have actually said, and help you take the next step.
Already bought or used some? Jump to what to do now.
RX Index Decision Verdict: Skip every compounded retatrutide offer. There is no legal version to buy.
- Best for: No one shopping for a compounded product. The verified paths to Lilly-made retatrutide are its trials and doctor-requested expanded access program.
- Not ideal for: Anyone, including people who have a prescription, a lab report, or a pharmacy name on the label.
- The factor that matters most: Whether the product has a legal path to you, not what the seller's paperwork says.
Decode the compounded retatrutide offer in front of you
Sellers use a handful of phrases to make retatrutide sound legal or official. None of them changes the FDA's position that retatrutide can't be compounded. Here's what each phrase actually means, with the source.
| What the offer says | What it actually means | Source |
|---|---|---|
| "Compounded at a licensed 503A pharmacy" | A pharmacy license doesn't make the ingredient eligible. A 503A pharmacy prepares patient-specific medicine under federal conditions. Retatrutide meets none of the applicable bulk-ingredient conditions. | FDA letter, Mar. 31, 2025 |
| "Made in an FDA-registered 503B facility" | 503B outsourcing facilities can prepare batches without patient-specific prescriptions. To use a bulk ingredient, they still need the applicable 503B-list or drug-shortage conditions met. Retatrutide meets neither. FDA has warned facilities for repackaging it. | FDA |
| "A licensed doctor prescribes it" | A prescription can't make an ingredient eligible. FDA has warned telehealth companies for marketing retatrutide, including straight to consumers. | FDA |
| "It's an off-label prescription" | Off-label means using an FDA-approved drug in a way its label doesn't cover. Retatrutide isn't approved, so there's no label to go "off." | FDA |
| "For research use only" or "not for human consumption" | FDA calls this label false when the product is sold to people with dosing instructions. Lilly has sued four peptide sellers over products marketed this way. | FDA; Lilly, Aug. 12, 2026 |
| "GLP-3," "RT," "Reta," "R-10," "R-20" | Nicknames for products sold as retatrutide. FDA warning letters dated Aug. 24, 2026 list "GLP-3 RT (Retatrutide)" and "GLP-3 Reta (Retatrutide)" by name. "GLP-3" is not the name of an FDA-approved retatrutide medicine. | FDA letter 733652; FDA letter 735063 |
| "Lab-tested, 99% pure" (a certificate of analysis) | A certificate of analysis reports tests on a sample. A purity result alone doesn't establish sterility, the labeled strength, or that the report matches your vial. It isn't FDA approval or proof that a product is safe to use. | FDA; Victoria health alert |
| "Same as Lilly's" or "trial-grade" | Lilly says it is the only lawful proprietor of retatrutide and that products offered for sale to consumers as retatrutide are unlawful. Trial results describe Lilly's product in Lilly's studies, not a seller's vial. | Lilly Medical |
| "Early access" | Real early access (expanded access) is started by your own treating doctor, who contacts Lilly. Lilly says it doesn't ship directly to patients through that program. A retail checkout page isn't expanded access. | Lilly Medical |
| "It's a legal gray area" | It isn't gray. FDA's current statement is plain: retatrutide can't be used in compounding under federal law. Even the compounding industry's trade group says it isn't eligible. | FDA; Alliance for Pharmacy Compounding |
If a seller uses any of these lines to justify selling you compounded retatrutide, none changes the answer.
This table explains claims. It can't clear a seller or tell you a product is safe to use.
Say a clinic messages you: "Retatrutide is finally here. Physician-prescribed, made at our licensed pharmacy, lab report included." That's three rows of the table in one sentence. None of the three changes the answer.
Once you set the retatrutide offer aside, the right next step still depends on you: your state, your insurance and formulary (the plan's covered-drug list), FDA-approved or compounded medicine, a shot or a pill, and your budget. The RX Index's Find My GLP-1 Path tool helps you compare a suggested path and providers. It's free, takes about 2 minutes, needs no signup, and asks a few quick questions about your goals, budget, insurance, and situation. It doesn't check your plan's coverage or decide what you can safely take.
Already bought or used it? Start here
The next step is medical help, not a different seller. Keep the product records, and tell a clinician exactly what you used.
If you bought it but haven't used it
Don't use an unapproved product labeled retatrutide. Keep the vial, the label, the box, the receipt, and any lab report for your clinician. Keep the product out of children's reach. A clinician can look at those with you. Whether the seller gives a refund depends on the seller.
If you used it, or you feel unwell
Call U.S. Poison Control at 1-800-222-1222. It's free and confidential. Call 911 right away if someone collapses, has a seizure, has trouble breathing, or can't be woken up (Poison Control).
Victoria's health department warns people who used products labeled retatrutide to watch for signs of liver injury: tiredness, belly pain, itchy skin, dark urine, yellow eyes or skin, and easy bruising. If you notice any of these, get medical care promptly (Victoria health alert).
We won't give doses, mixing steps, or a plan for stopping or switching. That's a conversation for your clinician, with the real product in front of them.
A message you can copy to your clinician:
I was offered, bought, or used a product labeled retatrutide. I'd like help reviewing the risks and deciding what to do next.
Product name and listed ingredients: ____ / unknown
Seller, clinic, or pharmacy on the label or receipt: ____ / unknown
I have / have not used it.
If used: dates and the amount I actually took, with units if known: ____ / unknown
Symptoms and when they started: ____ / none noticed
Other medicines and supplements I take: ____
Records I can share: label, box photos, receipt, any lab report
What should I do now? Would an FDA-approved treatment or a formal access program fit me?You can also report a problem with the product to the FDA through MedWatch. Lilly asks people to report illegal retatrutide products to the Lilly Answers Center at 1-800-LillyRx (Lilly).
What the Australian liver-injury cases do and don't show
Victoria's health department reported six cases of acute liver injury in Victoria since January 2026, in people who used unapproved products labeled Retatrutide, Reta, R-10, or R-20. The products were bought online, through friends, and through social media. Officials said a contaminant may be involved and that testing of the products was still underway (alert dated June 19, 2026).
That doesn't prove Lilly's study drug caused those injuries. It shows serious harm was reported after people used unapproved products carrying the retatrutide name. The alert did not establish the cause or prove contamination.
Why can't a pharmacy compound retatrutide?
Compounding from a bulk ingredient means making a medicine from that starting substance. It must meet the applicable federal ingredient rules. Retatrutide meets none of the paths below. That's why a license, a prescription, or a telehealth visit can't fix it.
Think of it like a recipe box. A compounding pharmacy may only cook from cards that are already in the box. Retatrutide doesn't have a card.
Here are the ingredient rules, in plain words, from the FDA's 2025 letter to state medical and pharmacy boards. The first three concern 503A; the final two concern 503B (FDA letter):
| Ingredient condition | What it means | Retatrutide |
|---|---|---|
| Official quality standard (USP or NF monograph) | A published standard for the ingredient | No |
| Part of an FDA-approved drug | The ingredient is in a medicine the FDA has approved | No |
| On FDA's 503A "bulks list" | A list of extra ingredients 503A pharmacies may use | No |
| On FDA's 503B "bulks list" | A list of ingredients outsourcing facilities may use | No |
| On FDA's drug shortage list | A route outsourcing facilities can use for drugs in short supply | No |
Why semaglutide and tirzepatide were different
Semaglutide and tirzepatide are the active ingredients in FDA-approved brands like Ozempic, Wegovy, Mounjaro, and Zepbound. When those approved injections were on FDA's shortage list, the rules allowed some compounding that would otherwise be restricted. The shortage-based exceptions and transition periods have ended (FDA's current policy; our guide to compounding rules after the shortage).
Retatrutide never had an approved version or an FDA drug-shortage listing. It never had that shortage-based compounding window.
Compounding isn't always illegal
Compounded medicines aren't FDA-approved, and the FDA doesn't review them for safety, effectiveness, or quality before they're sold. But compounding itself can be legal when the rules are met. The FDA says compounded drugs should be used only when a patient's medical need can't be met by an FDA-approved drug (FDA). That general rule doesn't help retatrutide, which the FDA singles out by name.
Every way you might get it, checked
| Where it's offered | Legal for retatrutide today? | Why |
|---|---|---|
| 503A compounding pharmacy | No | Meets none of the applicable bulk-ingredient conditions |
| 503B outsourcing facility | No | Not on the 503B list or shortage list |
| Ordinary commercial prescription from telehealth, a clinic, or a med spa | No | A prescription can't make the ingredient eligible; formal expanded access is separate |
| "Research peptide" website selling it for personal treatment | No | An unapproved drug marketed for human use, not participation in a clinical trial |
| Lilly clinical trial | Yes, if you qualify and a site is screening | Lilly makes and supplies the study drug |
| Lilly expanded access | Yes, for a very narrow group | Your treating doctor requests it from Lilly |
| Pharmacy prescription after approval | Not yet | Lilly plans to ask for approval in early 2027 |
Who has been warned or sued over retatrutide?
This isn't a theory. The FDA and Lilly have acted against several types of seller: telehealth companies, ingredient suppliers, outsourcing facilities, peptide shops, a med spa, and pharmacies. Lawsuits are allegations, not court findings. The dates below distinguish filed cases from later developments.
| Date | Who acted | What happened | Source |
|---|---|---|---|
| Mar. 31, 2025 | FDA | Wrote to state medical boards that compounded retatrutide doesn't qualify under 503A or 503B, and urged against buying unapproved retatrutide products | FDA letter |
| June 19, 2026 | Victoria Dept. of Health (Australia) | Health alert: six liver-injury cases in Victoria associated with products labeled retatrutide; cause under investigation | Alert |
| Aug. 12, 2026 | Eli Lilly | Announced six lawsuits against Aesthetic Envy (a California med spa), Striker Pharmacy, and four peptide sellers: Astra Peptides, Legendary Peptides, Texas Peptides, and Lone Star Peptide. Lilly said it had referred more than 200 people and entities to authorities and reported more than 14,000 websites, ads, social posts, and product listings in over 100 countries. | Lilly; Aesthetic Envy complaint |
| Aug. 24, 2026 | FDA | Warning letters to online peptide sellers, including NuScience Peptides and Peptide Partners, naming "GLP-3" retatrutide products | Letter 733652; Letter 735063 |
| Sept. 11, 2026 | Eli Lilly | Filed a notice dismissing its entire Aesthetic Envy case with prejudice. This was a voluntary dismissal, not a finding that a retatrutide product was safe or approved. | Filed dismissal notice |
| Oct. 1, 2026 (page update) | FDA | FDA's updated warning page reiterates that retatrutide can't be used in compounding and describes warnings to telehealth companies, ingredient distributors, and outsourcing facilities. This is a webpage update date, not when the restriction first began. | FDA |
For the wider picture across all GLP-1s, see our GLP-1 lawsuits and enforcement tracker.
Will compounded retatrutide ever be legal?
FDA approval would not automatically make compounded retatrutide legal. Approval could allow doctors to prescribe Lilly's product once it is available. Compounding would still depend on the applicable federal rules and how the product is approved.
Keep these four rules separate: one describes today, and the others concern what could happen after approval.
| Rule | What it means for compounded retatrutide | Source |
|---|---|---|
| 1. No eligible bulk-ingredient path today | Retatrutide has no applicable monograph, approved-drug component status, bulks-list entry, or drug-shortage listing | FDA |
| 2. The "copies" rule | Under 503A, regular or excessive compounding of essentially copies of commercially available drugs is restricted. A change can fall outside that definition when a prescriber documents a significant difference for a specific patient. The other conditions still apply. | FDA's 503A guidance |
| 3. The shortage route | A shortage-based exception depends on an FDA drug-shortage listing and the applicable compounding rules. Retatrutide has no such listing. The semaglutide and tirzepatide shortage-based exceptions have ended. | FDA's current policy; our compounding rules guide |
| 4. If it's licensed as a biologic | Lilly has gone to court arguing retatrutide should count as a biologic. FDA says biological products licensed under the Public Health Service Act do not qualify for the 503A or 503B exemptions. That is different from a blanket ban on every form of handling or repackaging. | Court order, Sept. 30, 2025; FDA notice to compounders |
So if you're waiting for a compounded version after approval, don't build your treatment budget around it. We found no announced commercial price in Lilly's current retatrutide information. Our retatrutide cost predictions page discusses forecasts, not a price you can act on.
How can you get real retatrutide today?
There are two verified medical access paths, and neither is a retail checkout. Both run through Lilly, and neither guarantees you'll get in.
1. A clinical trial. Search Lilly's trial finder for retatrutide and your location, then ask the study site if it's screening new people now. Some trials include a placebo (an inactive shot), so joining does not always mean receiving retatrutide. Check the specific study's treatment groups (Lilly's trial description).
2. Expanded access. This is a pre-approval program for a small group of very sick patients. Lilly lists five conditions, and you must meet all of them (Lilly Medical, last reviewed Aug. 26, 2026):
| Condition | In plain words |
|---|---|
| Age | 18 or older |
| Hard-to-treat obesity | BMI (body mass index, a weight-for-height number) of 35 or higher despite taking the highest available dose of chronic weight-management medicine as prescribed and tolerating it |
| Serious complications | Two or more serious or life-threatening obesity-related conditions you're already being treated for |
| No trial works | You can't join a retatrutide or similar trial, either because you don't qualify or there's no site you can reasonably reach |
| Options discussed | You and your doctor have talked through all standard options, including bariatric surgery |
Your treating doctor starts the request by calling Lilly at 1-800-545-5979. For this program, Lilly directs patients back to their doctor, and it doesn't ship to patients directly. Medical reasons that make retatrutide unsuitable exclude a patient. Supply, geography, and individual review also matter; meeting the five conditions is not an approval. The physician must complete the required FDA and ethics-review steps before treatment (Lilly Medical).
| Expanded access cost | What's known |
|---|---|
| The retatrutide itself | Lilly says it provides the drug at no cost |
| Doctor visits, tests, monitoring | Not stated. Ask your doctor and insurer. |
| Travel and other costs | Not stated. An unknown cost isn't zero. |
A free drug isn't the same as free care (Lilly's drug-supply terms). For trial details, timelines, and a checklist to take to your doctor, see our retatrutide availability guide. Check the date on any trial listing; this page has not confirmed a site is screening today.
What did you actually want? The closest legal path
You may have been looking for bigger results, a lower price, insurance help, a pill, or a next step after a plateau. The table shows what to discuss next—not a promise that you qualify. The alternative medicines are not retatrutide, and none should be described as a version of it.
A few quick questions help you find the relevant row:
- Is your BMI 30 or higher, or 27 or higher with a weight-related condition like high blood pressure? Those are common adult weight-management criteria, not the whole eligibility decision (Zepbound prescribing information).
- Do you have insurance with prescription coverage?
- Would you rather avoid needles?
- Are you already on a GLP-1 and stalled?
Not sure about your BMI or coverage? Leave that question open. Your clinician can assess eligibility, and your plan can confirm coverage; an unknown is not a yes or a no.
| What you wanted | What to discuss next | What it costs (checked Oct. 14, 2026) |
|---|---|---|
| An FDA-approved option with two of the three receptor targets | Zepbound (tirzepatide), FDA-approved. It acts on GIP and GLP-1 receptors, two of retatrutide's three targets. That does not make the results or medicines equivalent. | Through Ro: Zepbound KwikPen starts at $299 per 28-day supply at the starter strength, plus membership ($39 first month; then $149 monthly or $74/month equivalent with $888 paid annually). See the breakdown below. |
| Insurance to pay | An FDA-approved brand plus a coverage check | Ro's coverage check is free for the Ozempic, Wegovy, and Zepbound pens |
| No needles | Wegovy pill (semaglutide) or Foundayo pill (orforglipron), both FDA-approved | Through Ro: each starts at $149 for the starter-strength supply, plus membership. Higher-strength prices differ; for example, Wegovy 25 mg and Foundayo 9 mg are each listed at $299 per monthly supply, plus membership. |
| You are considering compounded medicine because an approved product cannot meet a specific medical need | A clinician's review of whether a patient-specific compounded product meets that need and the legal conditions. It is not FDA-approved or equivalent to Zepbound. | Embody advertises $119/month for compounded tirzepatide, but its linked terms list different prices. We could not verify what you would pay or renew at. See the conflict below before paying. |
| You stalled on your current GLP-1 | A treatment-plan review with your prescriber | Ask whether a visit or message carries a fee; do not assume it is free. See our GLP-1 plateau guide and what to try after Zepbound. |
| Real retatrutide and nothing else | A trial or expanded access | Lilly confirms no charge for its expanded-access drug; other care costs are not established. Ask the study team to explain trial costs before enrolling. |
The approved forms, prices, and refill conditions above come from the prescribing information, Wegovy label, Foundayo label, and Ro's price page; the detailed terms follow below.
Here's a made-up example. Say you're 44, paying cash for compounded tirzepatide, and your weight hasn't moved in eight weeks. Buying compounded retatrutide isn't a legal option. Your next steps are to ask your prescriber about your dose and plan, check whether insurance would cover an approved drug, or compare FDA-approved cash prices.
Check this first. If you're under 18, pregnant or trying to get pregnant, have type 1 diabetes, have a history of an eating disorder, or have a personal or family history of medullary thyroid cancer or MEN 2, talk with your own clinician before choosing a program. These situations do not all mean the same thing: medullary thyroid cancer and MEN 2 (an inherited endocrine disorder) are label contraindications for the medicines named here; the other situations need individual care. Start with our pages on GLP-1 hard contraindications and GLP-1s and pregnancy. The medicine-specific rules are in the Zepbound, Wegovy, and Foundayo prescribing information.
If you want an FDA-approved option
Ro doesn't offer retatrutide. There is no ordinary, lawful retatrutide prescription to fill. If retatrutide is the only thing you'll accept, check a trial or physician-requested expanded access—not a telehealth checkout.
Ro's weight-loss program offers FDA-approved medicines with ongoing prescriber support. If a clinician prescribes Zepbound, that is Lilly's approved tirzepatide product. Ro says its medication cash prices match LillyDirect, NovoCare, and TrumpRx; its membership is extra. Here are the membership and medication charges for one example, checked Oct. 14, 2026 (Ro pricing; Zepbound label):
| Cost piece | Amount | Notes |
|---|---|---|
| Ro membership, first month | $39 | Refunded if you're not eligible for a GLP-1 |
| Ro membership after month one | $149 month to month, or as low as $74 a month on a 12-month plan | The 12-month plan is prepaid: $888 up front |
| Zepbound KwikPen, 2.5 mg | $299 per 28-day supply | Billed separately from membership; this is a starter strength, not an approved maintenance dose |
| Zepbound KwikPen, 5 mg | $399 per 28-day supply | Your prescriber decides your dose |
| Zepbound KwikPen, 7.5 mg to 15 mg | $449 per 28-day supply | Manufacturer offer; continued eligibility requires a refill purchase within 45 days of receiving the previous supply |
| First membership month plus one 2.5 mg supply | $338 subtotal | $39 membership + $299 for 28 days of medicine; not an all-inclusive checkout quote |
Later costs depend on your prescribed strength and plan. For example, one month of membership plus one 28-day supply at the $449 offer price is a $598 subtotal ($149 + $449). A 28-day refill and a calendar-month membership do not stay on the same billing date. The $74 annual-plan figure is an average: the membership payment is $888 up front, not $74 each month.
Ro says membership includes provider support, check-ins, and lab testing if needed; medication is separate. Lilly says KwikPen needles are sold separately and taxes or fees may apply. We did not confirm whether Ro's selected fulfillment includes needles or any shipping charge, so neither subtotal assumes those costs are zero (Ro; Lilly).
The $449 offer is not the fallback price. Lilly lists regular self-pay prices of $499 at 7.5 mg and $699 at 10–15 mg when the purchase offer does not apply. Ro's page implies a lower non-offer figure for 10–15 mg, so ask for the actual charge before relying on a refill without the offer. Do not change treatment to meet a discount deadline (Lilly's terms; Ro's price page).
If an FDA-approved medicine with ongoing online care is what you were really after, Ro is one option to compare. Already have a prescriber? Ask about Lilly's self-pay pharmacy options before adding a separate membership.
See Ro's FDA-approved options (sponsored affiliate link, opens in a new tab)
If insurance should pay
Ro's free coverage check looks at your plan for the Ozempic, Wegovy, and Zepbound pens. You fill in details from your insurance card, and Ro emails you a report. It can't check the Zepbound KwikPen, the Foundayo pill, or the Wegovy pill right now (Ro checker). The report isn't a prescription or an approval.
On Medicare or Medicaid? Start with your own plan and your clinician first. Ro says Medicaid patients and people in some other government-funded programs are not eligible for its program (Ro's eligibility information). Do not treat its commercial-insurance checker as an answer about your government coverage.
If you have commercial insurance and want to know where you stand before you spend anything, the free coverage report is a useful first step.
Check your coverage with Ro (sponsored affiliate link, opens in a new tab)
If price is why you looked at compounded
A lower price alone does not make a compounded copy lawful. Compounded tirzepatide is not FDA-approved, and the FDA doesn't review it for safety, effectiveness, or quality. It isn't the same as Zepbound, and it isn't retatrutide. Tirzepatide's ingredient status differs from retatrutide's, but the remaining compounding conditions still apply. Ask your clinician whether an approved medicine cannot meet a specific medical need and whether a patient-specific change is appropriate—not just cheaper (FDA safety advice; FDA copies guidance).
Embody is a cash-pay telehealth program offering compounded semaglutide and tirzepatide. Its homepage and linked terms disagree on price. Here's what we found on Oct. 14, 2026 (Embody; terms, last updated Apr. 24, 2026; refund policy, last updated Aug. 25, 2026):
| What Embody shows | Detail |
|---|---|
| Compounded tirzepatide headline | "Flat rate at $119/month" |
| Plan lengths | Homepage: 4, 12, 24, or 52 weeks. We couldn't confirm which plan gets the $119 rate, the upfront amount, or the renewal charge. Four weeks is not a calendar month. |
| Price conflict | The linked terms list tirzepatide injections at $149 for month one and $399 afterward under the Start program, plus a different Flat schedule. Neither establishes the terms of the homepage's $119 offer. |
| Dose changes | Embody says the price stays the same when the dose changes within the same medicine and treatment plan |
| Insurance | Cash pay only |
| Before you pay | Payment is taken at checkout; clinical approval and a prescription are not guaranteed. Do not treat payment as an eligibility decision. |
| Cancellation | The terms and refund policy require a request at least 72 hours before the next billing date—not merely before shipment. |
| Refunds | Payments, including unused bundle portions, are generally nonrefundable. For provider-initiated medical disqualification, unused amounts are refunded less services already provided. |
Get written confirmation of the amount due today, the exact supply period, the renewal amount, and any extra fees before you pay. The homepage's shipment-based cancellation wording does not match the 72-hour billing deadline in its terms. Until the $119 offer is explained, it is not a verified treatment budget.
If your clinician has identified a medical reason for a compounded option, review Embody's current offer and payment terms. Confirm service in your state, the proposed prescription, and the pharmacy before proceeding; this page has not certified an individual prescription as lawful. Don't pay on the strength of the $119 headline alone.
See Embody's current pricing (sponsored affiliate link, opens in a new tab)
What we actually verified
We checked the regulator's statements, Lilly's own pages, and the price pages linked on this page. We didn't buy a product, test a vial, enroll in a trial, or complete a provider signup.
Checked October 14, 2026:
- FDA's current statement on unapproved GLP-1 drugs (page update dated Oct. 1, 2026); its March 31, 2025 retatrutide letter; and warning letters 733652 and 735063, dated Aug. 24, 2026
- FDA's current shortage/compounding policy, 503A copies guidance, off-label explanation, and notice on biological products
- Lilly's Aug. 12, 2026 lawsuit announcement; the Aesthetic Envy complaint and Sept. 11 dismissal notice; and the Sept. 30, 2025 court order documenting Lilly's biologic-classification challenge
- Lilly's July 23 and Sept. 29, 2026 filing plans and its retatrutide consumer-market and expanded-access pages; Lilly last reviewed those medical pages Aug. 4 and Aug. 26, 2026, respectively
- Victoria's June 19, 2026 health alert, Poison Control's guidance, and FDA's reporting links
- Current prescribing information for Zepbound, Wegovy, and Foundayo; Ro's pricing, checker, and insurance-eligibility pages; and Lilly's Zepbound self-pay terms
- Embody's homepage, terms, and cancellation/refund policy
What's provider-stated: Ro's and Embody's prices and terms are what their own pages said on Oct. 14, 2026. We checked the published statements, not a completed checkout, a delivered prescription, or an individual pharmacy's compliance.
What we couldn't confirm: the plan, upfront payment, and renewal terms behind Embody's $119 headline; the total cost of expanded-access care; or a current trial opening for any reader. We found pricing conflicts between Embody's homepage and terms, and between Ro's implied non-offer KwikPen price and Lilly's regular self-pay price. We verified the Aesthetic Envy dismissal, not the current disposition of all six lawsuits or the current outcome of the separate biologic-classification dispute.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Read our methodology.
Compounded retatrutide FAQ
Is compounded retatrutide legal?
No. The FDA says retatrutide cannot be used in compounding under federal law. A U.S. pharmacy license or prescription does not create an exception (FDA).
Can a pharmacy make retatrutide if I have a prescription?
No. A prescription doesn't change whether an ingredient can be compounded. Retatrutide meets none of the applicable bulk-ingredient conditions for 503A pharmacies or 503B facilities (FDA letter).
Is compounded retatrutide the same as Lilly's retatrutide?
A seller's claim does not establish that. Lilly says it is the only lawful proprietor of retatrutide and that products offered for sale to consumers as retatrutide are unlawful. Trial results come from Lilly's study drug, not proof about a seller's vial (Lilly Medical).
Why can tirzepatide be compounded but not retatrutide?
Tirzepatide is an ingredient in FDA-approved drugs; retatrutide meets none of the applicable bulk-ingredient conditions. The former shortage-based exceptions for tirzepatide have ended, so an ordinary monthly compounded copy is not automatically lawful. Patient-specific compounding must meet the remaining rules, and it still is not FDA-approved (FDA policy; copies guidance).
Is "research grade" retatrutide legal to buy?
For personal treatment, a "research grade" label does not make the offer lawful. FDA warns against products sold for human use behind research-only disclaimers; Lilly's August 2026 announcement included four peptide sellers. That is different from genuine nonclinical laboratory research (FDA; Lilly).
Will compounded retatrutide be available after FDA approval?
Don't count on approval creating a routine compounded alternative. Copying restrictions and other conditions would still matter. If retatrutide is licensed as a biological product, it would not qualify for the 503A or 503B exemptions (FDA copies guidance; biological-products notice).
What is GLP-3, RT, or Reta?
They're nicknames used for products sold as retatrutide, not names of an approved retatrutide medicine. Retatrutide is a triple agonist: it activates GIP, GLP-1, and glucagon receptors (Lilly). Learn more in what is retatrutide.
How much does compounded retatrutide cost?
We don't list prices for products that can't legally be sold for personal treatment, because no price tells you what's in the vial. We found no announced commercial price in Lilly's current retatrutide information. Our retatrutide cost predictions are forecasts, not a purchase quote.
I already took it. What should I do?
Tell a clinician what you used, when, and how much, and bring the label and receipt. For a suspected poisoning or an unexpected reaction, call Poison Control at 1-800-222-1222. Call 911 for collapse, seizure, trouble breathing, or if someone can't be woken (Poison Control).
When can I legally get retatrutide?
The two verified paths are a Lilly trial or doctor-requested expanded access, subject to screening and approval. Lilly plans to file for FDA approval in the first quarter of 2027; that is not an approval or launch date (Lilly; expanded access). Our retatrutide availability guide explains both paths.
Sources
Checked October 14, 2026 unless noted.
- FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (page updated Oct. 1, 2026; checked Oct. 14, 2026)
- FDA — Letter on compounded retatrutide to the Federation of State Medical Boards (Mar. 31, 2025); NABP copy via Ohio Board of Pharmacy
- FDA — Warning letter 733652, NuScience Peptides (Aug. 24, 2026)
- FDA — Warning letter 735063, Peptide Partners (Aug. 24, 2026)
- FDA — 503A guidance on compounded drugs that are essentially copies (Jan. 2018), read with FDA's current compounding-policy update (latest entry Apr. 1, 2026)
- FDA — Notice to compounders on biological products (Mar. 2020)
- FDA — Understanding unapproved use of approved drugs "off label"
- FDA — MedWatch reporting
- Eli Lilly — Lilly calls on platforms and regulators to shut down the illegal retatrutide black market (Aug. 12, 2026)
- Eli Lilly — Retatrutide successful in two additional Phase 3 obesity trials (July 23, 2026)
- Lilly Medical — Is retatrutide available in the consumer market?
- Lilly Medical — Is there an expanded access program for retatrutide? (last reviewed by Lilly Aug. 26, 2026)
- Eli Lilly — Clinical trial search
- Victoria Department of Health — Toxicity linked to unapproved peptide product labelled Retatrutide (issued June 19, 2026)
- Alliance for Pharmacy Compounding — Retatrutide (and other things that you shouldn't be compounding)
- Poison Control — poison.org
- Ro — Weight loss program pricing
- Ro — GLP-1 insurance checker
- Embody — Homepage pricing and disclosures
- Eli Lilly — Sept. 29, 2026 retatrutide update and filing plan
- Court filing — Aesthetic Envy complaint (Aug. 12, 2026) and notice of voluntary dismissal with prejudice (Sept. 11, 2026)
- U.S. District Court — Order in Lilly's FDA biological-product classification challenge (Sept. 30, 2025; not a current appellate-status report)
- Eli Lilly — Zepbound prescribing information and self-pay savings terms
- Novo Nordisk — Wegovy prescribing information, including tablets
- Eli Lilly — Foundayo prescribing information
- Ro — Insurance and program eligibility
- Embody — Terms & Conditions (last updated Apr. 24, 2026) and Subscription Services Cancellation & Refund Policy (last updated Aug. 25, 2026)